Satellos Bioscience (MSCL) Q2 2024 earnings summary

Executive summary

• Reported updated positive data from a canine model of Duchenne muscular dystrophy, showing a 195% improvement in muscle force over baseline at four months.

• Received Orphan Drug and Rare Pediatric Disease designations from the US FDA for SAT-3247.

• On track to dose the first participant in a Phase 1 clinical trial with SAT-3247 in Q3 2024.

Financial highlights

• Cash and cash equivalents and short-term investments totaled $27.7 million as of June 30, 2024, down from $39.6 million at December 31, 2023.

• Net loss for Q2 2024 was $6.0 million ($0.05 loss per share), compared to $4.1 million ($0.05 loss per share) in Q2 2023.

• Research and development expenses rose to $4.9 million in Q2 2024 from $1.6 million in Q2 2023, driven by increased headcount and preclinical activities.

• General and administrative expenses increased to $1.8 million in Q2 2024 from $1.5 million in Q2 2023, mainly due to higher personnel costs.

Outlook and guidance

• Plans to initiate a Phase 1a clinical trial of SAT-3247 in healthy volunteers in Q3 2024, with DMD patient trials expected to begin in early 2025.

• Expects to leverage preclinical and toxicology data for further clinical trials in Australia, the US, and Canada.